Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myelodysplastic Syndromes 3Small Cell Lung Carcinoma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rectal Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Kidney Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Gemcitabine 87Cisplatin 66Cystectomy 38pembrolizumab 34Docetaxel 25Nivolumab 24durvalumab 21Paclitaxel 19Magnetic Resonance Spectroscopy 18Radiotherapy 17Mitomycin 17Carboplatin 16atezolizumab 15Doxorubicin 14Cystoscopy 14BCG Vaccine 13Surveys and Questionnaires 12Standard of Care 12avelumab 11Sunitinib 10tremelimumab 9Transurethral Resection of Bladder 9Ipilimumab 9Filgrastim 9Blood Specimen Collection 9Specimen Handling 8Neoadjuvant Therapy 8Methotrexate 8Methods 8Early Intervention, Educational 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Neoplasms × guadecitabine × Clear all
NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡